Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone in Antipsychotic Naive/Quasi-Naive Children
NCT01731119Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Dec 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lurasidone in schizophrenia, schizoaffective disorder, schizophreniform disorder and 8 more, sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Percent Change in Weight at 12 weeks. Started Dec 2012; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorderpsychosisAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01731119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731119.